The relationship between positivity for COVID-19 RT-PCR and symptoms, clinical findings, and mortality in Turkey

Expert Rev Mol Diagn. 2021 Feb;21(2):245-250. doi: 10.1080/14737159.2021.1882305. Epub 2021 Feb 8.

Abstract

Introduction: This study aimed to assess the correlation between nucleic acid amplification test (real-time reverse transcription-polymerase chain reaction, RT-PCR) positivity of patients presenting with suspected COVID-19 and pneumonic infiltration consistent with COVID-19-specific pneumonia diagnosis on thoracic computed tomography (CT), with symptoms, laboratory findings, and clinical progression.Methods: The study included 286 patients (female:male 131:155; mean age, 53.3 ± 17.9 years) who were divided into two groups according to their RT-PCR test results. The symptoms, laboratory examinations, clinical findings, and thoracic CT imaging of the patients were evaluated.Results: While the physical examination, comorbidities, and total CT scores were similar between the groups, taste/smell abnormalities were observed more frequently in the PCR-positive group. The use of moxifloxacin, lopinavir/ritonavir, and tocilizumab was higher in the PCR-positive group (p = 0.016, p < 0.001, and p = 0.002, respectively). The duration of hospitalization, intensive care requirement, and mortality rate of the studied groups did not differ between the groups.Conclusions: Among patients presenting with suspected COVID-19 and pneumonic infiltration consistent with COVID-19 on thoracic CT, the symptoms, physical examination, total CT scores, duration of hospitalization, intensive care requirement, and mortality rate were similar between RT-PCR-positive and RT-PCR-negative patients. However, PCR-positive patients appeared to require more specific treatments.

Keywords: COVID-19; COVID-19 RT-PCR; SARS CoV-2; pneumonia.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • COVID-19 / diagnostic imaging*
  • COVID-19 / drug therapy
  • COVID-19 / mortality*
  • COVID-19 Nucleic Acid Testing*
  • Comorbidity
  • Female
  • Humans
  • Lopinavir / therapeutic use
  • Male
  • Middle Aged
  • Moxifloxacin / therapeutic use
  • Olfaction Disorders / complications
  • Radiography, Thoracic
  • Real-Time Polymerase Chain Reaction*
  • Ritonavir / therapeutic use
  • Taste Disorders / complications
  • Tomography, X-Ray Computed
  • Turkey / epidemiology

Substances

  • Antibodies, Monoclonal, Humanized
  • Lopinavir
  • tocilizumab
  • Ritonavir
  • Moxifloxacin

Grant support

This paper was not funded.